Dual Orexin-Kappa Receptor Modulators for Single-Drug Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and psychiatric disorders, such as substance addiction, PTSD, schizophrenia, anxiety, pain, depression, and Alzheimer's disease, are limited by the need for multiple medications and potential drug interactions, with single-target agents offering inadequate efficacy.
Innovation Solution
Development of dual-acting orexin and kappa-opioid receptor antagonists and modulators, specifically pyrazole and imidazole derivatives, to simultaneously modulate both receptor types, providing balanced therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple medications are used to treat neurological and psychiatric disorders, then treatment efficacy may be improved, but device complexity (number of medications) increases and drug interactions occur
Solution Approach 1:
The patent combines multiple receptor targeting activities into a single compound molecule. The dual-acting orexin and kappa-opioid receptor antagonists integrate two therapeutic mechanisms into one medication, eliminating the need for multiple separate drugs and reducing drug interaction complexity while maintaining comprehensive treatment efficacy.
Solution Approach 2:
The compound is designed with multi-functional properties, simultaneously acting as an orexin receptor antagonist and a kappa-opioid receptor antagonist. This universal design allows a single medication to address multiple neurological and psychiatric conditions that would traditionally require multiple specialized treatments.
2Device complexity
If single-target agents are used, then device complexity is reduced, but treatment efficacy becomes inadequate
Solution Approach 1:
The compound simultaneously targets both orexin and kappa-opioid receptors, providing multi-functional therapeutic activity in a single medication. This approach maintains simplicity (one drug) while achieving superior efficacy through dual mechanism of action, overcoming the limitations of single-target agents.
3Reliability
If dual-acting orexin and kappa-opioid receptor antagonists are developed, then treatment efficacy is improved and side effects are reduced, but manufacturing complexity increases
Solution Approach 1:
The molecular structure is segmented into distinct pharmacological modules: an orexin receptor binding moiety and a kappa-opioid receptor binding moiety. This segmentation allows independent optimization of each binding interaction while maintaining overall molecular integrity, facilitating systematic development and manufacturing of the dual-acting compound.
Data Source
AI summary
The present disclosure is directed to substituted Pyrazole and Imidazole derivatives of compounds that are antagonists and/or modulators of orexin and kappa-opioid receptors, and which are useful in the treatment or prevention of neurological, psychiatric, cardiovascular and cancer disorders and diseases in which orexin and kappa-opioid receptors are involved or implicated. The disclosure is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin and kappa-opioid receptors are involved.